Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

Breathe Right line extension expected to debut in March 2002, and CNS will enter a new product category later next year, company says during July 19 analysts call on Q2 results. Overall first-half sales reached $42.6 mil. compared to $27.9 mil. a year ago, while Q2 sales grew 16.5% to $15.5 mil., slightly outpacing earlier projections (1"The Tan Sheet" July 2, p. 8). "Disappointing" Fiberchoice sales of $5 mil. in first half causing CNS to reduce second-half marketing expenditures by about $7 mil. compared to first six months, company says

You may also be interested in...

CNS Restructuring Plan Focused On Bolstering Breathe Right Sales

CNS recorded a $1.2 mil. charge against earnings in the second quarter as part of a restructuring plan aimed at strengthening its core Breathe Right nasal strip business and returning the firm to sustainable profitability.

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts